Parnax Lab Ltd.

BSE: 506128 SECTOR: Pharmaceuticals & Drugs  1333   1   0

25.90
+0.05 (0.19%)
BSE: 22 Oct 05:10 PM

Price Summary

Today's High

₹ 25.95

Today's Low

₹ 25.1

52 Week High

₹ 39.05

52 Week Low

₹ 0

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

22.03 Cr.

Enterprise Value

32.97 Cr.

No. of Shares

0.85 Cr.

P/E

0

P/B

4.43

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  5.85

CASH

0.12 Cr.

DEBT

11.06 Cr.

Promoter Holding

62.59 %

EPS (TTM)

₹  -0.56

Sales Growth

18.28%

ROE

-29.37 %

ROCE

5.04%

Profit Growth

-142.25 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year18.28%
3 Year13.31%
5 Year-13.5%

Profit Growth

1 Year-142.25%
3 Year-200.17%
5 Year-20.05%

ROE%

1 Year-29.37%
3 Year-21.28%
5 Year-15.63%

ROCE %

1 Year5.04%
3 Year0.82%
5 Year0.55%

Debt/Equity

1.8995

Price to Cash Flow

10.03

Interest Cover Ratio

0.657587678478032

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 62.59 14.68
Mar 2021 62.59 14.68
Dec 2020 62.59 14.68
Sep 2020 62.59 14.68
Jun 2020 62.59 14.68
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 60.6263759921764 days.

 Limitations

  • The company has shown a poor profit growth of -200.167771989432% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.3079322906085% for the Past 3 years.
  • Company has a poor ROE of -21.2845922394804% over the past 3 years.
  • Company has a poor ROCE of 0.819365861983174% over the past 3 years
  • Company has low Interest coverage ratio of 0.657587678478032.
  • The company has a low EBITDA margin of -3.21137700914085% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 137.3727.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 0.22 0.7 0.68 0.77 1.74
Total Expenditure 0.37 0.67 0.8 0.98 1.29
Operating Profit -0.15 0.03 -0.12 -0.21 0.45
Other Income 0.01 0.03 0.03 0.01 0.03
Interest 0.22 0.22 0.21 0.18 0.18
Depreciation 0.01 0.01 0.01 0.01 0.01
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.37 -0.17 -0.31 -0.4 0.29
Tax 0 0 0 -0.12 0
Profit After Tax -0.37 -0.17 -0.31 -0.27 0.29
Adjusted EPS (Rs) -0.44 -0.2 -0.37 -0.32 0.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 7.23 5.28 5.8 6.49 7.68
Total Expenditure 7.64 5.28 6.91 6.39 7.14
Operating Profit -0.41 0 -1.11 0.11 0.53
Other Income 0.66 0.9 0.35 0.51 0.42
Interest 1.09 1.33 1.28 1.08 1.38
Depreciation 0.6 0.53 0.44 0.05 0.04
Exceptional Items 0 0 0 0 0
Profit Before Tax -1.43 -0.96 -2.48 -0.51 -0.47
Tax -0.41 -0.29 -0.08 0.32 1.53
Net Profit -1.01 -0.67 -2.4 -0.83 -2
Adjusted EPS (Rs.) -1.19 -0.78 -2.82 -0.97 -2.36

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 8.5 8.5 8.5 8.5 8.5
Total Reserves 3.1 2.48 0.15 -0.68 -2.68
Borrowings 12.58 6.53 8.38 8.33 2.77
Other N/C liabilities -2.54 -2.58 -2.9 -2.58 -1.05
Current liabilities 6.08 7.06 6.12 4.24 10.04
Total Liabilities 27.72 21.99 20.25 17.81 17.59
Assets
Net Block 6.69 6.36 0.62 0.57 0.53
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 10.71 10.13 10.02 10.07 10.07
Loans & Advances 0.1 0.01 0.05 0.05 0.05
Other N/C Assets 0 0 0 0 0
Current Assets 10.22 5.5 9.56 7.12 6.94
Total Assets 27.72 21.99 20.25 17.81 17.59
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations -1.43 -0.96 -2.48 -0.51 -0.47
Adjustment 0.83 2.02 3.41 1.19 1.42
Changes in Assets & Liabilities 2.5 2.59 -0.64 0.93 1.23
Tax Paid -0.12 0.02 0.36 0.07 0.02
Operating Cash Flow 1.78 3.67 0.64 1.68 2.2
Investing Cash Flow 0 0.34 0.12 0.03 -0.01
Financing Cash Flow -1.98 -3.78 -1 -2.25 -1.55
Net Cash Flow -0.2 0.23 -0.24 -0.55 0.64

Corporate Actions

Investors Details

PARTICULARS Jun 2020% Sep 2020% Dec 2020% Mar 2021% Jun 2021%
Promoters 62.59 62.59 62.59 62.59 62.59
binoy baiju shah 16.10 16.10 16.10 16.10 16.10
mihir prakash shah 13.42 13.42 13.42 13.42 13.42
prakash mahasukhla... 7.94 7.94 7.94 7.94 7.94
ila b shah 7.77 7.77 7.77 7.77 7.77
baiju mahasukhlal ... 7.39 7.39 7.39 7.39 7.39
pragna prakash shah 6.35 6.35 6.35 6.35 6.35
ami mihir shah 3.62 3.62 3.62 3.62 3.62
PARTICULARS Jun 2020% Sep 2020% Dec 2020% Mar 2021% Jun 2021%
Investors 37.41 37.41 37.41 37.41 37.41
dheeraj kumar lohia 1.67 1.79 1.79 1.78 1.82
suman gupta - - - 1.33 1.55
harsha n agarwal 1.29 1.29 1.29 1.29 1.29
llp - - - - 0.03

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Parnax Lab Stock Price Analysis and Quick Research Report. Is Parnax Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Parnax Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2.195265 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Parnax Lab has a Debt to Equity ratio of 1.8995 , which is a weak indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Parnax Lab , the EPS growth was -142.255113577963 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Parnax Lab has OPM of 6.9610791893579 % which is a bad sign for profitability.
     
  • ROE: Parnax Lab have a poor ROE of -29.3746979381688 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Parnax Lab

X